Pfizer and BioNTech announced on October 21 that a large-scale trial of their COVID-19 vaccine booster showed it restored full protection against the disease, said Xinhua, reported Bernama.
In a Phase 3 randomised, controlled trial, a Pfizer-BioNTech booster dose was administered to more than 10,000 individuals 16 years of age and older, who previously received the Pfizer-BioNTech primary two-dose series.
It showed a relative vaccine efficacy of 95.6% when compared to those who did not receive a booster.
These are the first efficacy results from any randomised, controlled COVID-19 vaccine booster trial.
“These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,” said Albert Bourla, Pfizer chairman and chief executive officer.
Last month, the US Food and Drug Administration authorised the booster shots for the Pfizer-BioNTech COVID-19 vaccine, allowing a single booster dose of the Pfizer-BioNTech vaccine be administered at least 6 months after completion of the primary series to individuals 65 years of age and older, and 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.